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Abstract
Objective—To evaluate diurnal variation in Optical Coherence Tomography (OCT) measured
retinal thickness in patients with center-involved diabetic macular edema (DME).
Methods—Serial OCT3 measurements were performed in 156 eyes of 96 subjects with clinically-
diagnosed DME and OCT central subfield retinal thickness ≥225 microns at 8 a.m. Central subfield
thickness was measured from OCT3 retinal thickness maps at 6 time points over a single day between
8 a.m. and 4 p.m. A change in central subfield thickening (observed thickness minus mean normal
thickness) of at least 25% and of at least 50 microns at two consecutive time points or between 8
a.m. and 4 p.m. was considered to have met the composite outcome threshold.
Results—At 8 a.m., the mean central subfield thickness was 368 microns and the mean visual acuity
was 66 letters (approximately 20/50). The mean change in relative central subfield retinal thickening
between 8 a.m. and 4 p.m. was a decrease of 6% (95% CI -9% to -3%) and the mean absolute change
was a decrease of 13 microns (95% CI -17 to -8). The absolute change was significantly greater in
retinas that were thicker at 8 a.m. (P <0.001) but the relative change was not (P=0.14). The composite
threshold of reduction in central subfield thickening (as defined above) was observed in 5 eyes of 4
subjects (3% of eyes, 95% CI, 1% to 8%) while 2 eyes of 2 subjects (1%, 95% CI, 0% to 5%) had
an increase in central subfield thickening of this same magnitude. The maximum decrease was
observed at 4 p.m. in all 5 eyes.
Conclusions—Although on average there are slight decreases in retinal thickening during the day,
most eyes with DME have little meaningful change in OCT central subfield thickening between 8
a.m. and 4 p.m.
Introduction
Optical Coherence Tomography (OCT) is a noninvasive method for measuring the thickness
of the central retina. It has become a standard tool in the management of patients with diabetic
macular edema (DME). This imaging technique uses low-coherence interferometry to produce
cross-sectional tomograms of the posterior segment eye structures. An 850 nm diode laser is
used to measure the delay in light backscattering from different layers in the retina, from which
the retinal thickness is calculated. Retinal thickness is determined from multiple individual
axial scans arrayed in a radial pattern along each of six linear segments all intersecting at the
center. A computer algorithm is used to determine the inner and outer retinal boundaries for
each scan.
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Several small studies have reported that retinal thickening may vary during the day in some
eyes with DME, generally being thickest in the morning and thinner later in the day.1–3 Since
OCT is a very sensitive method used to measure retinal thickening and judge response to DME
treatment in the clinic and in clinical trials, it is important to have reliable information on the
diurnal variation in retinal thickening. These findings will be essential for appropriate
interpretation of OCT results and/or the design of studies using this technique. We designed
the current study to evaluate retinal thickening measured by OCT throughout the day in eyes
with DME.
Methods
The study was conducted at 25 sites participating in the Diabetic Retinopathy Clinical Research
Network (DRCR.net). The study protocol was approved by the institutional review boards and
each subject gave written informed consent for participation in the study.
To be eligible, a subject was required to have at least one eye with (1) definite retinal thickening
due to DME based on clinical exam involving the center of the macula, (2) OCT central subfield
≥225 microns, (3) pupil dilation of 5 mm or larger, and (4) no treatment for DME within the
prior 3 months. Subjects were excluded if there was a history of chronic renal failure requiring
dialysis or kidney transplant, congestive heart failure currently under treatment, or blood
pressure >180/110.
Study Procedures
Retinal thickness measurements were made with the OCT3 system (Carl Zeiss Meditec,
Dublin, California) at 8 a.m., 9 a.m., 10 a.m., 12 noon, 2 p.m. and 4 p.m. (within ±30 minute
time windows). In addition at 8 a.m., 12 noon, and 4 p.m., the following were measured: visual
acuity (following a refraction) using the electronic ETDRS method,4 blood glucose using a
home glucose meter, and blood pressure. On the day of testing, or within one month of the
visit, fundus photographs were obtained. HbA1c was measured if not obtained during the prior
3 months. Additional health and past ocular history data were captured on electronic case report
forms (Table 1).
OCT Procedures
OCT images were obtained on each eye following pupil dilation by a certified operator using
the OCT3 system. The same operator obtained the OCT images once at each time point. A
second measurement at each time point was made by the same operator or a different operator.
Scans of inadequate quality (e.g., standard deviation >10% or signal strength score <6) were
to be repeated until they met these specified quality metrics. Scans were sent to the DRCR.net
Reading Center at the University of Wisconsin-Madison for grading. For scans with standard
deviations ≥10.5% of the center point thickness, inaccurately drawn automated boundary lines,
or decentration,5 center point thickness was measured manually with calipers from the retina
thickness map scans (13% of images). For such scans, central subfield thickness was imputed
from the manually-determined center point thickness using a regression equation (since the
correlation of the two measurements was 0.98 for 897 automated measurements).
Statistical Considerations
The sample size was estimated to be 120 eyes such that the half-width of a 95% confidence
interval on a 0.20 point estimate of the proportion of eyes experiencing meaningful diurnal
variation would be 0.07 and on a 0.10 point estimate would be 0.05.
Change in central subfield thickening was the primary outcome variable. Only eyes with both
8 a.m. and 4 p.m. OCT scans in which the 8 a.m. central subfield thickness was ≥225 microns
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and the initial OCT scan was obtained within ±45 minutes of 8 a.m. (analysis window 30
minutes larger than the protocol specified time window) were included in the analysis. Eleven
subjects did not have either eye meeting these criteria and were excluded from analyses. OCT
measurements obtained twice at the same time point were averaged for analysis.
Retinal thickening, i.e. excess retinal thickness, was defined as the observed thickness minus
the mean normal central subfield thickness of 202 microns (based on unpublished data provided
by Carl Zeiss Meditec from a study of 260 nondiabetic eyes with a normal macula). Therefore,
relative change in retinal thickening was calculated as (4 p.m. thickness minus 8 a.m.
thickness)/(8 a.m. thickness minus mean normal thickness). The mean change in absolute and
relative retinal thickening in the central subfield between 8 a.m. and 4 p.m. was computed and
a 95% confidence interval constructed, accounting for the inter-eye correlation in subjects with
two study eyes using repeated measures mixed models. The proportions of study eyes with
change in central subfield thickening meeting the composite threshold endpoint of at least 25%
and at least 50 microns at consecutive time points or between 8 a.m. and 4 p.m. were calculated.
The proportion of eyes with a change in central subfield thickening of at least 50 microns was
also calculated. The threshold of 25% was arbitrarily chosen as a relative change that was likely
to be clinically meaningful. The threshold of 50 microns was likewise considered to be
clinically meaningful and exceeded the 95% half-width confidence interval for detection of
change of 40 microns (based on reproducibility data from 1147 eyes). The composite endpoint
was chosen to utilize the relative change measurement while assuring that the magnitude of
change exceeded this 95% confidence interval and was clinically meaningful. Results were
evaluated in three subgroups based on the baseline central subfield retinal thickness: 225–300
microns, 301–450 microns, and >450 microns. The effect of baseline thickness on the change
in thickening from 8 a.m. to 4 p.m. was assessed using a repeated measures model adjusting
for inter-eye correlation in subjects with two study eyes. The effects of additional clinical and
ocular characteristics on the mean change in central subfield thickening were evaluated by
ANCOVA also adjusting for 8 a.m. central subfield thickness and accounting for inter-eye
correlation. Correlations were used to define the relationship between change in central
subfield thickening and the change in visual acuity or blood glucose. They were calculated in
repeated measures models (to account for the correlation within subjects with two study eyes)
based on the likelihood ratio as defined by Magee.6 To satisfy parametric assumptions change
in visual acuity was truncated at ±3 standard deviations from the mean, truncation did not
meaningfully change the results. Statistical analyses were performed using SAS software
version 9.1.
Results
The study included 96 subjects, of whom 36 (38%) had one study eye and 60 (63%) two study
eyes, for a total of 156 study eyes. The baseline characteristics of the subjects and study eyes
are shown in Table 1. Among the 156 study eyes, the mean central subfield retinal thickness
at baseline (8 a.m.) was 368 ± 132 microns. There were 71 (46%) study eyes with baseline
thickness of 225–300 microns, 53 (34%) with 301–450 microns, and 32 (21%) with >450
microns. Of the 96 subjects included in the analyses all with 8 a.m. and 4 p.m. measurements,
one subject missed both 9 a.m. measurements and 2 subjects missed the second 10 a.m.
measurement. All 96 subjects completed both measurements at 12 p.m. and 2 p.m.
The mean change in relative central subfield retinal thickening from 8 a.m. to 4 p.m. was a
decrease of 6% (95% confidence interval -9% to -3%) and the mean absolute change was a
decrease of 13 microns (95% confidence interval -17 to -8, Figure 1 and Table 2). Five eyes
(3%, 95% confidence interval 1% to 8%) of 4 subjects reached the predefined composite
outcome of ≥25% decrease in central retinal thickening and ≥50 micron decrease in central
retinal thickening between 8 a.m. and 4 p.m. (Table 3). There were no additional eyes that met
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these criteria at two consecutive earlier time points but not between 8 a.m. and 4 p.m. Among
the 5 eyes reaching the composite decrease in central subfield thickening, this decrease was
first achieved at 2 p.m. in 2 eyes, and 4 p.m. in 3 eyes. The maximum relative decrease was
observed at 4 p.m. in all 5 eyes (Figure 2). Two eyes (1%, 95% confidence interval 0% to 5%)
of 2 subjects reached the predefined composite outcome for an increase in central subfield
thickening ≥25% and ≥50 microns. Tables 2 and 3 detail these changes subgrouped by 8 a.m.
central subfield thickness. On avera2ge, central subfield thickening decreased throughout the
day by approximately 9.2 microns (95% confidence interval 6.1 to 12.2) for every 100 microns
of increased central subfield thickness at 8 a.m., but there was considerable variation between
individuals (Figure 3). The absolute change was significantly greater in retinas that were thicker
at 8 a.m. (P<0.001) but the relative change was not (P=0.14) (Table 2). No additional factors
were found to be significantly associated with the degree of diurnal change (P≥0.01, Table 4).
From 8 a.m. to 4 p.m. best corrected E-ETDRS visual acuity letter score increased on average
by 1.0 letters (95% confidence interval −0.05 to +2.1 letters, Figure 4), improving by ≥10 letters
in 16 eyes (10%) and worsening by ≥10 letters in 9 eyes (6%). Of the 5 eyes with the composite
outcome for a reduction in retinal thickening, visual acuity improved ≥5 letters in 1 eye,
worsened ≥5 letters in 2 eyes, and changed <5 letters in 2 eyes. Change in retinal thickening
from 8 a.m. to 4 p.m. correlated poorly with change in visual acuity (r=−0.05, Figure 4),
reflecting the large proportion of eyes with little change in thickening and the variability
inherent in the measurements of both acuity and retinal thickening.
Blood glucose concentration increased from 8 a.m. to 4 p.m. ≥50 mg/dl in 21 of the 95 subjects
(8 a.m. blood glucose for one subject was missing) and decreased by ≥50 mg/dl in 23 subjects.
Change in retinal thickening from 8 a.m. to 4 p.m. correlated weakly (r=−0.13) with change
in blood glucose.
Results for other OCT measures such as center point thickness, average of central and inner
subfield thickness, and macular volume were similar to the results for the central subfield (data
not shown).
Discussion
This study demonstrates that although on average there are slight decreases in retinal thickening
during the day, most eyes with DME have little meaningful change in OCT central subfield
thickening between 8 a.m. and 4 p.m. Only 3% of eyes (5 of 156) met the composite threshold
of both ≥25% and ≥50 micron decrease in retinal thickening at two consecutive time points or
between 8 a.m. and 4 p.m. However, 2 eyes (1%) increased by these amounts over this period
as well. While a change in retinal thickening of 50 microns may be a meaningful clinical change
in an individual patient, with current OCT technology it is not possible to differentiate true
change in retinal thickening from the variability of measurement when the difference is less
than 40 microns, the measurement of variability.
A study by Frank, et al.1 suggested that OCT measured retinal thickening in DME varied
according to time of day. In that study of 10 subjects, retinal thickness was measured at 8:00
a.m., 11:00 a.m., 2:00 p.m., and 5:00 p.m. Four of the 10 subjects had decreased thickening in
one or more macular subfields in one or both eyes over the course of the day. The eyes with
greater initial retinal thickening tended to show a greater absolute decline over the day than
did the eyes with less initial thickening. The magnitude of the decrease in retinal thickening
was relatively small (estimated at approximately a mean of 15 microns from the published
figures), although statistically significant by paired t-test comparing 8 a.m. with later times. In
the study by Frank, et al., almost all of the change in retinal thickening occurred by 11 a.m. In
contrast, the 5 eyes in our study with a composite decrease in retinal thickening changed
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throughout the data collection period through the final 4 p.m. evaluation (Figure 2). An earlier
study by Sternberg, et al.7 that employed psychovisual assessments of three patients with DME
noted that visual function in patients with macular edema may vary with time of day, being
generally worse in the morning. Such a finding supports the anatomic observations in the study
by Frank, et al. Both authors suggested that the diurnal change may be related to nocturnal
recumbency playing a role in retinal vascular homeostasis. In both studies, patients were
admitted to the hospital so that the measurements could be obtained immediately on arising, a
methodological difference from the current study. Larsen, et al.2 evaluated change in retinal
thickening from evening to morning in 12 eyes of 12 patients with DME. There was a
statistically significant mean increase in thickening overnight of 21 microns in the DME group,
which was statistically significant compared with the results in 14 eyes of 7 nondiabetic control
subjects. Reproducibility of measurements was not addressed in that study using the OCT1
machine. Patients with DME also demonstrated a mean loss of 5 ETDRS letters of acuity
overnight. Recently, Polito, et al.,3 published data from 15 eyes of diabetic macular edema
patients and 10 eyes of non-diabetic controls who had OCT3 fast macular thickness map scans
at four time points between 9 a.m. and 6 p.m. on a single day. They did not detect any suggestion
of diurnal variation in the control eyes or the macular edema eyes with center subfield thickness
<300 microns. However, they found that among the 9 eyes with center subfield thickness ≥300
microns, 4 demonstrated a consistent decrease in thickness over the course of the day and this
subgroup had a mean decrease of central subfield thickness of 9.4%. Two of these 4 eyes had
a 5 letter increase in visual acuity.
Our data suggest that decreasing retinal thickening in eyes with DME is a real phenomenon
that may occur over the course of a single day in some patients. This change is generally of
small magnitude and only occasionally achieves levels that may be considered clinically
relevant. Indeed, the mean change of approximately −15 microns measured in a small cohort
of DME patients by Frank, et al.,1 and the 9.4% reduction measured among 9 subjects by Polito,
et al.3 during daytime hours are similar to the mean change in the 301–450 micron group in
our study.
There was also little correlation between change in retinal thickening and change in visual
acuity. This is in agreement with the study of Larsen, et al.2 and not surprising given the small
absolute changes in retinal thickening noted in this study. A separate paper authored by the
DRCRnet details the relationship between central retinal thickening and visual acuity both
before and after laser photocoagulation.8
In summary, although some patients with CSME appear to have progressive decreases in retinal
thickening during the course of the day, the extent and frequency of these changes do not appear
to be of a sufficient magnitude to substantially impact clinical trials (especially if there is a
randomly assigned control group and no systematic difference between treatment groups in
the time of day of measurement). Our study did not address whether the meaningful diurnal
changes exhibited by the small number of patients would be consistently present on a daily
basis. However, the clinical impact of these changes is likely to be small.
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Figure 1.
Box-whisker plot demonstrating mean (dashed horizontal line), median (solid horizontal line),
25–75th percentiles (extremes of the box), 10–90th percentiles (whiskers), and 5–95th
percentiles (solid circles) for change in central subfield thickening from baseline at each time
point.
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Figure 2.
Central Subfield Thickness throughout the Day for Eyes with Relative Decrease ≥25% and
Absolute Decrease ≥50 Microns
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Figure 3.
Absolute Change in Central Subfield Thickening from 8 a.m. to 4 p.m. by 8 a.m. The solid line
represents the regression line and the dotted lines represent the 95% confidence interval for
the mean.
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Figure 4.
Box-whisker plot demonstrating mean (dashed horizontal line), median (solid horizontal line),
25–75th percentiles (extremes of the box), 10–90th percentiles (whiskers), and 5–95th
percentiles (solid circles) for change in visual acuity from baseline at each time point.
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Figure 5.
Absolute Change in Central Subfield Thickening on OCT versus Change in Visual Acuity from
8 a.m. to 4 p.m.
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Table 1
Baseline Demographis and Clinical Characteristics
Subject Characteristics N=96
Gender: Women - N (%) 44 (46%)
Age (years) - Mean ± SD 59 ± 11
Race - N (%)
 White 65 (68%)
 African-American 14 (15%)
 Hispanic 15 (16%)
 Other 2 (2%)
Diabetes Type - N (%)
 Type 1 14 (15%)
 Type 2 79 (82%)
 Uncertain 3 (3%)
Duration of Diabetes (years) - Mean ± SD 17 ± 9
Currently Medically Treated for Hypertension - N (%) 73 (76%)
History of Sleep Apnea - N (%) 20 (21%)
History of Chronic Obstructive Pulmonary Disease - N (%) 0 (0%)
Time Subject in Bed Prior Night (hours) - Mean ± SD 6.7 ± 1.4
HbA1c (%)* - Mean ± SD 7.8 ± 1.6
Blood Glucose mg/dl (8 a.m.) † - Mean ± SD 178 ± 65
Body Mass Index (kg/m2) 34 ± 6
Baseline (8 a.m.) Eye Characteristics N=156
Central subfield Thickness (8 a.m.) – N (%)
 225–300 microns 71 (46%)
 301–450 microns 53 (34%)
 >450 microns 32 (21%)
 Mean ± SD – microns 368 ± 132
Cysts on OCT‡ - N (%)
 None/Questionable 42 (27%)
 Definite 111 (73%)
Visual Acuity (8 a.m.) - N(%)
 ≥84 letters (20/20 or better) 15 (10%)
 83–68 letters (20/25 to 20/40) 73 (47%)
 67–51 letters (20/50 to 20/100) 42 (27%)
 50–36 letters (20/125 to 20/200) 19 (12%)
 ≤35 letters (worse than 20/200) 7 (4%)
 Mean ± SD - Snellen Equivalent 20/50 ± 3.4 lines
Prior Treatment for DME - N (%) 124 (79%)
 Laser Photocoagulation - N (%) 117 (75%)
 Intravitreal Triamcinolone Injection - N (%) 27 (17%)
 Peribulbar Triamcinolone Injection - N (%) 8 (5%)
 Vitrectomy - N (%) 13 (8%)
Prior Scatter Photocoagulation - N (%) 34 (22%)
Prior Cataract Extraction - N (%) 42 (26%)
*
Four subjects with missing HbA1c lab values.
†
1 subject had missing blood glucose value.
‡
Cystoid space ungradable on 3 scans.
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Table 2
Change in Central Subfield Thickening from 8 a.m. to 4 p.m. According to 8 a.m. Thickness (156 eyes from 96
subjects)
Change in Central Subfield Thickening Mean (95% Confidence Interval)*
Total N Relative Change in Thickening Absolute Change (Microns)
Overall 156 −6% (−9%, −3%) −13 (−17, −8)
Central Subfield Thickness (8
a.m.)
 225–300 microns 71 −4%(−10%, +2%) −4 (−8, 0)
 301–450 microns 53 −8% (−11%, −4%) −14 (−20, −8)
 >450 microns 32 −8% (−13%, −2%) −30 (−48, −11)
P-value† for Effect of 8 a.m.
Thickness on Change
0.14 <0.001
*
Accounting for the inter-eye correlation within subjects with two study eyes.
†
P-value calculated from repeated measures mixed model regressing change in thickness from 8 a.m. to 4 p.m. on 8 a.m. thickness.
Note: Negative change implies decrease in thickening.
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Table 4
Evaluation of Diurnal Change According to Clinical Characteristics (N=156 Eyes of 96 Patients)
Change in Central Subfield Thickening from 8 a.m. to 4 p.m.
Stratified by Baseline Characteristics
N Absolute Mean Change in
Central Subfield Thickening
± SD (8 a.m. to 4 p.m.)
P-value*
Patient Characteristics
Gender 0.79
 Women 64 −13 ± 34
 Men 92 −12 ± 23
Race 0.07
 White 111 −8 ± 26
 African American 19 −29 ± 32
 Hispanic 24 −19 ± 27
Diabetes Type† 0.47
 Type I 21 −17 ± 31
 Type II 129 −12 ± 27
HbA1c 0.67
 <8% 99 −13 ± 25
 ≥8% 52 −13 ± 33
Sleep Apnea 0.01
 Yes 32 −25 ± 30
 No 124 −9 ± 26
BMI (kg/m2) 0.03
 ≤25 14 +2 ± 42
 >25 142 −14 ± 26
Ocular Characteristics
Prior Treatment for DME 0.65
 Yes 124 −14 ± 28
 No 32 −6 ± 26
Prior Laser Photocoagulation 0.80
 Yes 117 −13 ± 27
 No 39 −10 ± 29
Prior Scatter Photocoagulation 0.75
 Yes 34 −13 ± 39
 No 122 −12 ± 24
Prior Cataract Extraction 0.76
 Yes 42 −9 ± 29
 No 114 −14 ± 27
Prior Vitrectomy 0.13
 Yes 13 −23 ± 36
 No 143 −12 ± 27
Visual Acuity (8 a.m.) - N (%) 0.72
 20/40 or better 82 −7 ± 21
 20/50–20/100 52 −19 ± 28
 Worse than 20/125 22 −17 ± 42
Cystoid Space on OCT‡ 0.42
 None/Questionable 42 −2 ± 13
 Definite 111 −16 ± 31
*
P-value obtained from ANCOVA, adjusted for 8 a.m. central subfield thickness and accounting for correlation within subjects with two study eyes.
†
N=6 eyes of 3 subjects that were uncertain of their diabetes type were not included.
‡
have ungradeable cystoid spaces.
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